dMed, a Shangai, China-based clinical CRO, completed a US$100m Series C financing.
The round was led by Fidelity Management & Research Company, LLC, with participation from new investors Sequoia Capital China, Kaiser Foundation Hospitals and E Fund, and existing backers Qiming Venture Partners, Lilly Asia Ventures, and Vivo Capital.
Led by Founder, Chairman and CEO, Dr. Lingshi Tan, dMed is a full-service Clinical Contract Research Organization (CRO), which provides industry solutions to pharmaceutical and medical device companies in China and across the globe. The company leverages and integrates China’s new regulatory framework to offer innovative drug development strategies, and help clients expand globally by tapping into the world’s second largest pharmaceutical market. Its collaboration models will help Chinese and global innovative pharma companies raise efficiency in clinical R&D, scientifically shorten research cycle, and boost success rate.
dMed’s business covers consulting, regulatory affairs & strategy, early clinical development, clinical science & medical affairs, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, quality assurance and information solutions.
The company has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs around 600 professionals globally.